Biotech Values

[masterlongevity]

I don't think the deal will close prior to the adjuvant data unless Roche offers a significant permium to their initial offer. I think the chances are pretty high for positive Adj data. They have reported over and over that there are no significant safety issues, the drug works in later stage and the MOA makes more sense for early stage CRC. i think DNA is stalling and for good reason.